BioCentury
ARTICLE | Company News

Emergent submits BLA for anthrax treatment

August 8, 2014 2:14 AM UTC

Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) submitted a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. Emergent gained rights to the product -- a solution of human polyclonal antibodies that target anthrax toxins -- through its acquisition of Cangene Corp. earlier this year. AIGIV is being developed under a $160 million contract with HHS's Biomedical Advanced Research and Development Authority (BARDA). Since the contract was awarded in 2005, 10,000 doses have been delivered to the U.S. Strategic National Stockpile. ...